Kim Yong Tai, Rha Sun Young, Shim Chi Young, Sohn Joo Hyuk, Kim Chul, Yu Nae Choon, Chung Hyun Cheol, Kim Joo Hang, Han Dae Suk, Kim Byung Soo, Roh Jae Kyung
Department of Internal Medicine, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea.
Yonsei Med J. 2003 Jun 30;44(3):539-43. doi: 10.3349/ymj.2003.44.3.539.
Nephrotic syndrome is a rare manifestation of malignancy associated with paraneoplastic syndrome. Paraneoplastic nephrotic syndrome has been reported in various malignancies: malignant lymphoma, colon cancer, lung cancer and prostate cancer. However, an ovarian carcinoma associated with nephrotic syndrome has rarely been reported. Only six cases of ovarian carcinoma associated paraneoplastic nephrotic syndrome has been reported worldwide, but no cases have been reported in Korea. Here, we report a case of paraneoplastic nephrotic syndrome in a patient with an ovarian carcinoma. The patient presented with ascites, proteinuria and hypoalbuminemia. An initial computed tomography (CT) scan and ultrasonography evaluations showed no specific findings suggestive of an ovarian tumor. Despite treatment for nephrotic syndrome, the symptoms became more aggravated. There after, follow up evaluation at Yonsei University Medical Center, including serum CA 125, pelvis MRI and peritoneal fluid examination were performed. On the pelvis MRI, a left ovarian mass was detected with an ascitic fluid collection. The serum CA 125 level was elevated to 2211 U/ml. The peritoneal fluid cytological examination showed malignant cells suggestive of an ovarian carcinoma. Combination chemotherapies including paclitaxel plus carboplatin, topotecan plus gemcitabine and oxaliplatin plus capecitabine were administered to the patient, and complete remission was achieved on image and tumor marker studies. There was complete recovery from the nephrotic syndrome with no evidence of ascites and proteinuria. These findings suggest that nephrotic syndrome caused by paraneoplastic syndrome can be resolved only after the complete control of the underlying malignancy.
肾病综合征是与副肿瘤综合征相关的恶性肿瘤的一种罕见表现。副肿瘤性肾病综合征已在多种恶性肿瘤中被报道:恶性淋巴瘤、结肠癌、肺癌和前列腺癌。然而,与肾病综合征相关的卵巢癌却鲜有报道。全球仅报道了6例与副肿瘤性肾病综合征相关的卵巢癌病例,但韩国尚无此类病例报道。在此,我们报告一例卵巢癌患者并发副肿瘤性肾病综合征的病例。该患者表现为腹水、蛋白尿和低蛋白血症。最初的计算机断层扫描(CT)和超声检查未发现提示卵巢肿瘤的特异性表现。尽管对肾病综合征进行了治疗,但症状却加重了。此后,在延世大学医学中心进行了进一步评估,包括血清CA 125检测、盆腔磁共振成像(MRI)和腹水检查。盆腔MRI检查发现左侧卵巢有肿物并伴有腹水。血清CA 125水平升高至2211 U/ml。腹水细胞学检查发现恶性细胞,提示为卵巢癌。患者接受了包括紫杉醇加卡铂、拓扑替康加吉西他滨以及奥沙利铂加卡培他滨的联合化疗,影像学和肿瘤标志物检查显示达到完全缓解。肾病综合征完全康复,无腹水和蛋白尿迹象。这些发现表明,由副肿瘤综合征引起的肾病综合征只有在潜在恶性肿瘤得到完全控制后才能得到解决。